Of the nine clinical trials that were launched against the target of three—so we're very pleased that we could over-deliver on that front—the first trial, which I spoke to briefly, Bruce Perkins' trial at the University Health Network in Toronto, has finished enrollment and is just finalizing its collection of data. The first reports on that will be out. Clinical trials by their very nature take time, so the data will be coming out from each of these trial networks over the next three to four years. The shortest trial is Bruce Perkins', which, as I say, is wrapping up now, and three years out from now we should see data from the pregnancy, or CONCEPTT, trial.
Thus far, I'll say we've had unparalleled success in recruitment. One of the great measures of how you're doing within clinical trials is how well you're recruiting. Canada, which certainly hasn't had as many clinical trials available to the diabetic population as we've seen, say, in the United States, is over-recruiting. In fact, one of the trials, the AdDIT trial, which is being done in conjunction with the United Kingdom, has completed the Canadian portion of recruitment and is now over-recruiting and picking up some of the U.K.'s portion. So thus far, we're seeing really great success, great strides forward.
Then there's somebody like Maksim, who testified here before you today, who is participating in the CGM TIME trial. That trial, which is being run here out of the Children's Hospital of Eastern Ontario, but at four sites across Ontario, has actually over-delivered on its recruitment targets as well. As you can see, it's having a direct impact on the lives of Canadians as we sit here today.